Ainos, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
AIMD Nasdaq 3840 www.ainos.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ainos, Inc.

Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025 - Jan 21st, 2025 3:00 pm
Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule - Jan 17th, 2025 2:00 pm
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots - Jan 13th, 2025 3:00 pm
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA - Dec 18th, 2024 5:05 pm
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA - Dec 18th, 2024 1:00 pm
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement - Dec 13th, 2024 1:00 pm
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing - Dec 4th, 2024 1:00 pm
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug - Dec 2nd, 2024 1:00 pm
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments - Nov 13th, 2024 1:00 pm
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 - Nov 11th, 2024 1:00 pm
Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023) - Nov 9th, 2024 12:40 pm
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities - Nov 8th, 2024 1:00 pm
Ainos Reports Third Quarter 2024 Financial Results - Nov 6th, 2024 9:30 pm
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets - Oct 28th, 2024 12:00 pm
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast - Oct 24th, 2024 2:50 pm
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies - Oct 7th, 2024 12:00 pm
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA - Sep 25th, 2024 12:00 pm
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome - Sep 24th, 2024 2:55 pm
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options - Sep 23rd, 2024 12:00 pm
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts - Sep 20th, 2024 12:00 pm